
("
Convatec announces pricing of $500 Million 5.300% Senior Notes due 2035
For more information, please refer to our announcement published on
Enquiries
Media: MediaRelations@convatec.com
Investor Relations: IR@convatec.com
About
Pioneering trusted medical solutions to improve the lives we touch:
Notes
The offering is being made by means of an offering memorandum. This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security and shall not constitute an offer, solicitation or sale in
The Notes and the related guarantees have not been, and will not be, registered under the
This announcement has been prepared on the basis that any offer of the Notes (i) in any Member State of the European Economic Area (the "EEA") will be made pursuant to an exemption under Regulation (EU) 2017/1129 (as amended or superseded, the "Prospectus Regulation") from the requirement to publish a prospectus for offers of the Notes; and (ii) in the
PROHIBITION OF SALES TO EEA RETAIL INVESTORS - The Notes are not intended to be offered, sold, or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the EEA. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU of the
PROHIBITION OF SALES TO
MiFID II and
The distribution of this announcement into certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdiction.
Forward-looking Statements
This announcement may include "forward-looking statements" within the meaning of the securities laws of certain applicable jurisdictions. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts contained in this announcement, including, without limitation, those regarding the offering of the Notes and the details thereof and the proposed use of proceeds therefrom. Forward-looking statements are generally identified by the use of terms such as "believes", "estimates", "anticipates", "expects", "intends", "predicts", "may", "will", "could", "targets", or their negatives or other similar expressions. Forward-looking statements are based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to business, economic and competitive uncertainties that are difficult to predict and are outside the Company's control, including, but not limited to: access to and reliability of the Company's supply chain; the Company's dependence on a number of single source suppliers; environmental, health and safety laws and regulations, and numerous permit requirements and licensing regimes; and operational risks. Forward-looking statements are based only on knowledge and information available to the Company at the date of this document and speak only as at the date of this document. The Company has no obligation to update any forward-looking statements (except to the extent required by applicable law or regulation).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the